Clinical trials: Fat; Liver
Obesity, Atherosclerosis
Observational Study of Early Metabolic and Vascular Changes in Obesity
To work against the increasing burden of obesity, the STYJOBS / EDECTA (STYrian Juvenile OBesity Study / Early DetECtion of Atherosclerosis) project was started at the Medical University of Graz in 2003.
- Conditions
- Obesity, Atherosclerosis, Inflammation, Adiponectin Deficiency
- Trial name
- STYJOBS (NCT00482924)
- Testing
- Lifestyle intervention
- Where
- Austria
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Non-alcoholic Fatty Liver Disease (NAFLD)
Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study
Metformin is being compared to exercise and diet modifications. The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating the condition or disorder.
- Trial name
- NCT02457286
- Testing
- Metformin, Lifestyle modifications, Fibroscan device (Echosens)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwell Health
Obesity
South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease
People with BMI >30 kg/m2 will be included in at population-based cohort. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included.
- Trial name
- SDOI (NCT05176132)
- Testing
- Life style intervention (dietician+ physiotherapist), Self management, No intervention
- Where
- Denmark
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Claus Bogh Juhl
Healthy Participants
Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants
This Phase I, randomised, single-blind, placebo-controlled study has been designed to assess the safety, tolerability, and pharmacokinetics (PK) of AZD2693 following subcutaneous (SC) administration of AZD2693 in healthy…
- Trial name
- NCT05107336
- Testing
- AZD2693
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
NAFLD, Insulin Resistance
Determination of Insulin-stimulated Hepatic Glucose Uptake by PET-CT Measurements
In the absence of excessive alcohol consumption, increased levels of fat in the liver (>5%) are diagnosed as non-alcoholic fatty liver (NAFL).
- Conditions
- NAFLD, Insulin Resistance, Overweight and Obesity
- Trial name
- ISGU (NCT04938544)
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Nonalcoholic Steatohepatitis
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).
- Trial name
- NCT00227110
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Non-Alcoholic Fatty Liver Disease, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH
A study for evaluating the improvement effect on Metabolic dysfunction-associated steatotic liver disease (MASLD) of probiotics Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with dysbiosis of the…
- Trial name
- NCT04555434
- Testing
- Probiotics
- Where
- South Korea
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Effect of Vitamin A and Calcium in Patients With Non-alcoholic Fatty Liver Patients
Effect of Vitamin A and Calcium in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease at a global scale and is strongly associated with the obesity and metabolic syndrome .
- Trial name
- NCT06031532
- Where
- Egypt
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sohag University
Liver Neoplasm, HBV Infection
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma…
- Conditions
- Liver Neoplasm, HBV Infection, Non-alcoholic Fatty Liver Disease NAFLD, Liver Fibrosis
- Trial name
- NCT07265544
- Testing
- Collection of Preoperative Peripheral Blood, Collection of Discarded Liver Tissue During Surgery
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
NAFLD (Nonalcoholic Fatty Liver Disease)
Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions
It is a 12-week study. The participants will follow three different diets, and during each diet period, and the participants will wear our device, and blood samples will be collected.
- Trial name
- NCT06932289
- Testing
- Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF), The integrated sweat sensor and vascular sensor (wearable), continuous glucose monitor (CGM)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Greater Los Angeles Healthcare System
Healthy Volunteers (Non-alcoholic Steatohepatitis)
A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.
The study will investigate the influence of NNC0194-0499 on the blood levels of the two components of a birth control pill, Microgynon®.
- Trial name
- NCT06188026
- Testing
- NNC0194-0499, ethinylestradiol/levonorgestrel
- Where
- Austria
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Metabolic Dysfunction-associated Fatty Liver Disease
An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines With Metabolic Dysfunction-associated Fatty Liver Disease
Investigating the association between intestinal Ruminococcus gnavus and its derived biogenic amines with metabolic dysfunction-associated fatty liver disease
- Trial name
- NCT07455149
- Testing
- observational study, no intervention
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital